RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company, primarily focused on gastrointestinal diseases. RedHill commercializes and promotes four gastrointestinal products in the U.S. RedHill has a robust and de-risked clinical late-stage pipeline with several Phase 3 and Phase 2-stage drugs in development. RedHill has successfully completed four Phase 3 studies (2x Talicia® (RHB-105) for H. pylori infection, RHB-104 for Crohn’s disease & BEKINDA® (RHB-102) for gastroenteritis). RedHill plans to file an NDA for Talicia® for H. pylori infection in H1/2019 (eligible for 6-month priority review) and expects to launch Talicia® in Q4/2019, subject to FDA approval.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):